Summary
Precigen: Entering The Oncology 'Sweet Spot'
Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call.
Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Precigen Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 36 | $150 | $182.47 | $32.47 | 21.65% |
 Farallon Capital Farallon Capital Management LLC | 50,000 | $209,000 | $255,250 | $46,250 | 22.13% |
| BG Bart Gancher Intech Investment Management LLC | 44,638 | $74,949.15 | $225,984.34 | $151,035.19 | 201.52% |
| KAC Kimberly A. Clarke Stoneridge Investment Partners LLC | 16,126 | $25,652.43 | $81,639.49 | $55,987.06 | 218.25% |
 Point72 Asset Management LP Point72 Asset Management LP | 6.64M | $27.77M | $33.72M | $5.95M | 21.41% |
Precigen Inc. (PGEN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Precigen Inc. ever had a stock split?
Precigen Inc. Profile
| Biotechnology Industry | Healthcare Sector | Helen Sabzevari CEO | NASDAQ (NGS) Exchange | 74017N105 CUSIP |
| US Country | 160 Employees | - Last Dividend | - Last Split | 8 Aug 2013 IPO Date |
Overview
Precigen, Inc., previously known as Intrexon Corporation until February 2020, was founded in 1998 and is based in Germantown, Maryland. As a discovery and clinical-stage biopharmaceutical entity, Precigen focuses on the fabrication of gene and cell therapies. These therapies leverage precision technology to specifically target a range of diseases across three major therapeutic areas: immuno-oncology, autoimmune disorders, and infectious diseases. The company's operational structure is streamlined into two segments: Biopharmaceuticals and Exemplar. Through its advanced therapeutic platforms and a strong commitment to innovation, Precigen aims to address some of the most challenging medical conditions with next-generation treatment options.
Products and Services
- UltraCAR-T Therapies
- AdenoVerse Immunotherapy
- ActoBiotics
- UltraPorator
- Research Models and Services
This proprietary technology provides chimeric antigen receptor T cell therapies aimed at treating cancer. It represents a significant part of Precigen's focus in immuno-oncology, exemplified by its ongoing clinical trials including PRGN-3005 for advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 for advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic and solid tumors.
Utilizing a library of proprietary adenovectors, this platform is designed for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens. Currently, ongoing programs based on this platform include PRGN-2009 for patients with HPV-associated cancer and PRGN-2012 for treating recurrent respiratory papillomatosis.
A unique platform aimed at disease modification through the manipulation of the microbiome. An example of this technology in action is AG019, currently in a Phase 1b/2a trial for the treatment of type 1 diabetes mellitus.
A proprietary electroporation device developed by Precigen to enhance the delivery and efficiency of its gene and cell therapy treatments. This technology is indicative of the company’s investment in not just developing therapies but also enhancing the methods by which these therapies are administered.
Precigen also engages in the development of research models and services, catering to a wide array of healthcare research applications. This reflects the company's broader commitment to supporting the scientific community in understanding and combating diseases more effectively.
